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Background: Irinotecan (I) combined with Carboplatin (C) has proven 
to be an active combination in-patient with extensive stage SCLC. We 
conducted a prospective phase II study to determine the activity and 
safety of this combination with CT/RT in previously untreated LS-
SCLC pts. 
Patients and methods: The main objective was response rate (RR) and 
the secondary safety and overall survival. Eligibility included: measur-
able disease, ECOG PS 0-2, informed consent and adequate hepatic, 
renal and bone marrow function. Treatment consisted of: I 60mg/m2 IV 
followed for C AUC = 3 IV D1, 8 Q 21D for 6 cycles, and concurrent 
RT 2.0 Gy daily to a total of 60.0 Gy, beginning in the 2nd cycle. The 
dose of I and C was reduced to 50 mg/m2 and AUC: 2 respectively dur-
ing CT/RT (cycles: 2nd - 4th). Patients with complete response (CR) 
received PCI (2.0 Gy X 10) after completion chemotherapy.
Results: 30 pts were enrolled, 22 male and 8 female. Median age was 
71 years (range 43- 81); 76% had PS 0 or 1.
Twenty-eight pts were evaluable for response. The total number of 
cycles administered was 161 with a median of 6 (range 2-6). The rela-
tive dose-intensities of I and C were 84% and 87% respectively. The 
median of follow-up was 14 months. In intent to treat analysis the RR 
was 92.7%, twenty pts achieved a CR and 8 pts a PR. Median survival 
was 22 months. Grade 3-4 (NCI-CTC 3.0) toxicity (per cycle) included: 
neutropenia (14%), thrombocytopenia (14%), anemia (5%), diarrhea 
(12%), vomiting (5%). There were two episodes of typhitis and three 
episodes of febrile neutropenia, however there were no treatment-re-
lated deaths. 
Conclusions: IC combined with early CR/RT is highly active with a 
favorable median survival. The proﬁle of safety is adequate in pts with 
LS-SCLC. Further development of this combination is warranted. 
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Background: Patients with limited disease SCLC were treated up till 
2001 with sequential chemoradiotherapy (SCT) and from 2001 with 
concurrent chemoradiotherapy (CCT). The optimal treatment has yet 
to be deﬁned. This retrospective study analysed the efﬁcacy of both 
treatments. 
Methods: Between 1991 until December 2000, 69 SCT pts were in-
cluded, and from 2001 until February 2005 40 pts who underwent CCT.
In SCT, the chemotherapy consisted of 5 cycles of cyclophosphamide, 
doxorubicin and etoposide. In case of complete remission, radiotherapy 
was given in once-daily fractions of 2.5 Gy, 5 fractions/week, to a total 
dose of 40 Gy. Prophylactic cranial irradiation (PCI) was given in 15 
fractions of 2 Gy, 5 fractions/week.
In CCT, radiotherapy was started on day 22 after start chemotherapy. 
The fraction dose was 1.8 Gy, 5 fractions/week, the total dose was 45 
Gy. Chemotherapy consisted of 4 or 5 cycles of cisplatin and etopside. 
PCI was applied to patients who had achieved a complete response. 
Primary endpoints are radiological response, median survival time and 
3- and 4-year overall survival; secondary endpoints include causes of 
death, frequency of metastases and toxicity.
The Kaplan-Meier method was applied to determine the median sur-
vival time and the survival rates. 
Results: The mean and median tumour volume of SCT pts was 142 
and 81cm3, those of CCT pts 117.6 and 40 cm3, resp. The mean overall 
treatment time of SCT was 182 d, and that of CCT 89 d.
The radiological complete response of SCT pts was 95.6%, of pts with 
CCT 60%. PCI was applied to 95.6% of the SCT pts and to 57.5% of 
the CCT pts. 
The SCT median survival time was 24.9±3.0 month; the 3- and 4-year 
overall survival were 38.8±6.1 and 31.5±6.0%, respectively. The CCT 
median survival time was 23.8±4.2 month and the 3- and 4-year overall 
survival 36.7±8.3 and 31.5±8.6 %, respectively.
Of the 69 SCT pts, 51 had died of which 38 pts (74.5%) with tumour 
and 21 of 24 CCT pts (87.5%). 
Grade3/4 haematological side effects were reported in 47 (68%) SCT 
pts and in 18 (45%) CCT pts.
Symptomatic radiation oesophagitis was observed in 41 (59%) of SCT 
pts and in 19 (47.5%) of the CCT pts. 
Brain metastases were diagnosed in 12 (17%) SCT pts and in 13 
(32.5%) CCT pts. 
The mean interval time for SCT pts between restaging after chemo-
therapy and start of radiotherapy was 52.3 d, the median 47 d, and the 
range 21-173 d.
Conclusions: Although a higher mean and median tumour volume, a 
better radiological response was obtained for the SCT pts. The median 
survival time and the 3- and 4-y survival rates were not signiﬁcantly 
different. The frequency of brain metastases in CCT pts was twice of 
that of SCT pts.
We advise to perform a prospective randomised trial comparing SCT 
and CCT. Better results might be expected with SCT schemes for 
smaller tumour volumes and a smaller interval time between end of 
chemo- and start of radiotherapy.
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SCLC represents about 20% of LC patients in most developed 
countries, it has poor prognosis with 10% survival at 2 years. In this 
retrospective study there were 80(6%) patients with SCLC among 
1274 LC patients admitted to the INT between 1994-2001. Four cases 
had incomplete data. We analyzed the prognostic factors, treatment, 
outcome and survival of the 76 cases; 63 with Limited Disease (L.D) 
and 13 with Extended Disease (E.D). Twelve (16%) patients did not 
experience weight loss and 25(33%) patients (27% in LD and 62% in 
ED) lost more than 10% in six months. Karnofski PS (KPS) less than 
70% had 25 (33%) patients (30% with L.D and 46% with E.D) 
From the 32 (42%) patients who received chemoradiotherapy (CTRT) 
(Cisplatin Etoposide and RT) in other oncology institutions, median 
